Stay updated on CTA and Methylation in NSCLC Response to Pembrolizumab Clinical Trial

Sign up to get notified when there's something new on the CTA and Methylation in NSCLC Response to Pembrolizumab Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the CTA and Methylation in NSCLC Response to Pembrolizumab Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a potential update in the dosage or frequency of administration of Pembrolizumab, a humanized monoclonal antibody used in the treatment of non-small cell lung cancer patients with specific PD-L1 expression levels.
    Difference
    0.1%
    Check dated 2024-06-06T14:35:52.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying requirements such as having untreated advanced stage lung adenocarcinoma and being at least 18 years old, among other health and consent conditions.
    Difference
    42%
    Check dated 2024-05-22T21:30:54.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:40:33.000Z thumbnail image

Stay in the know with updates to CTA and Methylation in NSCLC Response to Pembrolizumab Clinical Trial

Enter your email address, and we'll notify you when there's something new on the CTA and Methylation in NSCLC Response to Pembrolizumab Clinical Trial page.